Clinical Trial

Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease

Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This study evaluates the efficacy and safety of the addition of Firsekibart to standard initial treatment (intravenous immunoglobulin \[IVIG\] plus aspirin) in children with Acute Kawasaki Disease (KD) .
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-07-06; most recent amendment 2026-07-24.
Trial Details
NCT Number NCT07686770
Lead Sponsor Children's Hospital of Fudan University
Collaborators: Jiangxi Province Children's Hospital
Conditions Kawasaki Disease
Enrollment 90 participants
Start Date 2026-08-01
Primary Completion 2027-09-01 (estimated)
Study Completion 2028-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-27